Real-world treatment of chronic rhinosinusitis with dupilumab and omalizumab: results from the Korean National Health Insurance Service database
The results of this study which analysed real-world data in a large population, suggest a discrepancy between the recommended dose and real-world administration of biologics. Further studies are warranted on feasible administration schedules that reflect various patient factors and healthcare costs.
Authors
- B H Kim
- Yong Bae Kim (ORCID: https://orcid.org/0000-0001-7573-6862)
- Ju Young Yoon (ORCID: https://orcid.org/0000-0003-3944-0663)
- Cheon‐Gyu Cho (ORCID: https://orcid.org/0000-0003-4851-5671)
- J H Park
- Jiyeon Kim (ORCID: https://orcid.org/0009-0005-1875-9861)
- Sun A Han (ORCID: https://orcid.org/0000-0001-7646-8038)
- YS Lim
- SW Park
Institutions
- Dongguk University (KR)
- Dongguk University Ilsan Hospital (KR)
Publication Details
- Journal
- Rhinology Journal
- Published
- 2025-02-01
- DOI
- https://doi.org/10.4193/rhin24.209
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00